MedTrace Logo

Vamikibart in Participants With Uveitic Macular Edema

NCT05642325 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2026-04-17

No results posted yet for this study

Summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Conditions

  • Uveitic Macular Edema

Interventions

DRUG

Vamikibart

Participants will receive vamikibart IVT injection

OTHER

Sham

Participants will receive a sham procedure that mimics an IVT injection.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-LaRoche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-23
Primary Completion
2025-05-07
Completion
2025-12-24
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • China
  • Czechia
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Kazakhstan
  • Portugal
  • Singapore
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642325 on ClinicalTrials.gov